NOTE 1 – BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements include the accounts of Zivo Bioscience, Inc. and its wholly-owned subsidiaries (collectively, the “Company”).  All significant inter-company accounts and transactions have been eliminated in consolidation.  In the opinion of the Company’s management, the financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the information set forth therein.  These consolidated financial statements are condensed, and therefore do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.  These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s  December 31, 2014 consolidated audited financial statements and supplementary data included in the Annual Report on Form 10-K filed with the SEC on April 6, 2015.

The results of operations for the six months ended June 30, 2015 are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2015, or any other period.

The Company had a loss from operations of $1,604,227 and $1,579,468 for the six months ended June 30, 2015 and 2014, respectively.  In addition, the Company had a working capital deficiency of $7,129,595 and a stockholders’ deficit of $7,954,319 at June 30, 2015.  These factors continue to raise substantial doubt about the Company's ability to continue as a going concern.  During the first six months of 2015, the Company raised $48,500 in net proceeds from the sale of common stock, $1,067,500 from the issuance of Convertible Debt and $152,891 from net loans payable to related parties.  There can be no assurance that the Company will be able to raise additional capital.